Year None20262025202420232022202120202019201820172016 June 26, 2026 Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights Go to June 11, 2026 Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms Go to June 3, 2026 Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 Go to May 28, 2026 Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs Go to May 22, 2026 Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet Go to May 19, 2026 Medicenna Announces the Finalization of the Terms of its Public Offering of Securities Go to Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
June 26, 2026 Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights Go to
June 11, 2026 Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms Go to
June 3, 2026 Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 Go to
May 28, 2026 Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs Go to
May 22, 2026 Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet Go to
May 19, 2026 Medicenna Announces the Finalization of the Terms of its Public Offering of Securities Go to
